Skip to main content

Home/ Nutrition/ Group items tagged hnca

Rss Feed Group items tagged

Matti Narkia

Unexpected Perks of Coffee Consumption - The Early Show - CBS News - 0 views

    "(CBS) Your daily cup of java may deliver some unexpected health benefits. Studies have shown it may lower your risk for Type II diabetes and certain types of cancer (colon, mouth and throat), and protect against heart disease and cavities.

    Dr. Alanna Levine, a primary care physician, said on "The Early Show" researchers aren't sure exactly why coffee has these benefits, but speculated that perhaps the coffee has antioxidant properties. "
Matti Narkia

Vitamin D levels associated with survival in lymphoma patients - 0 views

    ScienceDaily (Dec. 5, 2009) - A new study has found that the amount of vitamin D in patients being treated for diffuse large B-cell lymphoma was strongly associated with cancer progression and overall survival. The results will be presented at the annual meeting of the American Society of Hematology in New Orleans.

    Also, several recent reports have concluded that vitamin D deficiency is associated with poor outcomes in other cancers, including breast, colon and head and neck cancer. This is the first study to look at lymphoma outcome
Matti Narkia

Berberine inhibits human tongue squamous carcinoma cancer tumor growth in a murine xeno... - 0 views

    Berberine inhibits human tongue squamous carcinoma cancer tumor growth in a murine xenograft model.
    Ho YT, Yang JS, Lu CC, Chiang JH, Li TC, Lin JJ, Lai KC, Liao CL, Lin JG, Chung JG.
    Phytomedicine. 2009 Sep;16(9):887-90. Epub 2009 Mar 20.
    PMID: 19303753

    Our primary studies showed that berberine induced apoptosis in human tongue cancer SCC-4 cells in vitro. But there is no report to show berberine inhibited SCC-4 cancer cells in vivo on a murine xenograft animal model. SCC-4 tumor cells were implanted into mice and groups of mice were treated with vehicle, berberine (10mg/kg of body weight) and doxorubicin (4mg/kg of body weight). The tested agents were injected once per four days intraperitoneally (i.p.), with treatment starting 4 weeks prior to cells inoculation. Treatment with 4mg/kg of doxorubicin or with 10mg/kg of berberine resulted in a reduction in tumor incidence. Tumor size in xenograft mice treated with 10mg/kg berberine was significantly smaller than that in the control group. Our findings indicated that berbeirne inhibits tumor growth in a xenograft animal model. Therefore, berberine may represent a tongue cancer preventive agent and can be used in clinic.
Matti Narkia

Head And Neck Cancer Survivors Who Use Alcohol And Cigarettes Have Increased Death Risk - 0 views

    "Cigarette smoking and alcohol consumption before head and neck cancer diagnosis strongly predicts the patient's future risk of death, according to published studies. Now, results of a new study show a similar effect among those who continued these habits after cancer diagnosis.

    "Most cancer survivors are counseled to quit smoking; despite this, many still smoke. In our study, 21 percent continued to smoke even after their cancer diagnosis, increasing their risk of death," said researcher Susan T. Mayne, Ph.D. "Similarly, we found that continued drinking increases the risk of death.""
Matti Narkia

Berberine Inhibits Metastasis of Nasopharyngeal Carcinoma 5-8F Cells by Targeting Rho K... - 0 views

    Berberine inhibits metastasis of nasopharyngeal carcinoma 5-8F cells by targeting Rho kinase-mediated Ezrin phosphorylation at threonine 567.
    Tang F, Wang D, Duan C, Huang D, Wu Y, Chen Y, Wang W, Xie C, Meng J, Wang L, Wu B, Liu S, Tian D, Zhu F, He Z, Deng F, Cao Y.
    J Biol Chem. 2009 Oct 2;284(40):27456-66. Epub 2009 Aug 3.
    PMID: 19651779
Matti Narkia

Berberine suppresses in vitro migration and invasion of human SCC-4 tongue sq... - 0 views

    Berberine suppresses in vitro migration and invasion of human SCC-4 tongue squamous cancer cells through the inhibitions of FAK, IKK, NF-kappaB, u-PA and MMP-2 and -9.
    Ho YT, Yang JS, Li TC, Lin JJ, Lin JG, Lai KC, Ma CY, Wood WG, Chung JG.
    Cancer Lett. 2009 Jul 8;279(2):155-62. Epub 2009 Feb 28.
    PMID: 19251361

    There is increasing evidence that urokinase-type plasminogen activator (u-PA) and matrix metalloproteinases (MMPs) play an important role in cancer metastasis and angiogenesis. Inhibition of u-PA and MMPs could suppress migration and invasion of cancer cells. Berberine, one of the main constituents of the plant Rhizoma coptidis, is a type of isoquinoline alkaloid, reported to have anti-cancer effects in different human cancer cell lines. There is however, no available information on effects of berberine on migration and invasion of human tongue cancer cells. Here, we report that berberine inhibited migration and invasion of human SCC-4 tongue squamous carcinoma cells. This action was mediated by the p-JNK, p-ERK, p-p38, IκK and NF-κB signaling pathways resulting in inhibition of MMP-2 and -9 in human SCC-4 tongue squamous carcinoma cells. Our Western blowing analysis also showed that berberine inhibited the levels of urokinase-plasminogen activator (u-PA). These results suggest that berberine down-regulates u-PA, MMP-2 and -9 expressions in SCC-4 cells through the FAK, IKK and NF-κB mediated pathways and a novel function of berberine is to inhibit the invasive capacity of malignant cells.
Matti Narkia

Dietary vitamin D and cancers of the oral cavity and esophagus -- Lipworth et al. 20 (9... - 0 views

    Dietary vitamin D and cancers of the oral cavity and esophagus.
    Lipworth L, Rossi M, McLaughlin JK, Negri E, Talamini R, Levi F, Franceschi S, La Vecchia C.
    Ann Oncol. 2009 Sep;20(9):1576-81. Epub 2009 Jun 1.
    PMID: 19487490

    Conclusion: We observed inverse associations between dietary vitamin D intake and risk of SCCE and, perhaps, oral/pharyngeal cancer, which were most pronounced among heavy current smokers and heavy consumers of alcohol.
Matti Narkia

DCA and vanadium combination - The DCA Site - Updating You on DCA and Cancer - Dichloro... - 0 views

    Simultaneously Blocking Glycolysis and Fat Metabolism

    Can the use of DCA and a fatty acid metabolism blocker together force more cancer cells into using aerobic metabolism?

    Tim McGough used green tea extract, which contains EGCG, in his fantastic response.

    DCA works by reactivating mitochondria and shifts metabolism from glycolysis to glucose oxidation. Hopefully the cancer cell will then undergo apoptosis. However, cancer cells have an alternate energy source: fat metabolism. This page explores to possibility of blocking fat metabolism to help force the cell into apoptosis.

    Oral squamous cell carcinoma is a cancer that does not respond well to DCA. This study, Head and Neck Cancer Cell Lines Are Resistant to Mitochondrial-Depolarization-Induced Apoptosis states:

    "Results: ΔΨm in head and neck cell lines started to show slight loss of ΔΨm, while HL-60 showed significant loss of ΔΨm after 30 min of treatment. All cell lines demonstrated complete mitochondrial depolarization within 24 h, however, only the control cell line HL-60 underwent apoptosis. In addition, HNSCC cell lines did not demonstrate cytoplasmic cytochrome c release despite significant mitochondrial membrane depolarization, while HL-60 cell initiated apoptosis and cytochcrome c release after 24 h of treatment. Conclusions: Head and neck cancer cell lines exhibit defects in mitochondrial-membrane-depolarization-induced apoptosis as well as impaired release of cytochrome c despite significant mitochondrial membrane depolarization. Proximal defects in the mitochondrial apoptosis pathway are a feature of HNSCC.(head and neck squamous cell carcinoma)"

    Note that although the cell lines were depolarized, apoptosis did not occur. So I checked to see if fatty acid metabolism is used by squamous cell carcinoma.
Matti Narkia

The beverage maté: a risk factor for cancer of the head and neck. - Head Neck... - 0 views

    The beverage maté: a risk factor for cancer of the head and neck.
    Goldenberg D, Golz A, Joachims HZ.
    Head Neck. 2003 Jul;25(7):595-601. Review.
    PMID: 12808663
    DOI: 10.1002/hed.10288
Matti Narkia

Maté: a risk factor for oral and oropharyngeal cancer - Oral Oncol. 2002 Oct;... - 0 views

    Maté: a risk factor for oral and oropharyngeal cancer.
    Goldenberg D.
    Oral Oncol. 2002 Oct;38(7):646-9. Review.
    PMID: 12167417

Matti Narkia

Perioperative immunonutrition in head and neck cancer. - Wiley InterScience :: JOURNALS... - 0 views

    Perioperative immunonutrition in head and neck cancer.
    Sorensen LD, McCarthy M, Baumgartner MB, Demars CS.
    Laryngoscope. 2009 May 20. [Epub ahead of print]
    PMID: 19459146
    DOI: 10.1002/lary.20494
Matti Narkia

Selenium and immunocompetence in patients with head and neck cancer. - Biol Trace Elem ... - 0 views

    Selenium and immunocompetence in patients with head and neck cancer.
    Kiremidjian-Schumacher L, Roy M, Glickman R, Schneider K, Rothstein S, Cooper J, Hochster H, Kim M, Newman R.
    Biol Trace Elem Res. 2000 Feb;73(2):97-111.
    PMID: 11049203
    DOI: 10.1385/BTER:73:2:97
Matti Narkia

Combination Immunotherapy of Squamous Cell Carcinoma of the Head and Neck: A Phase 2 Tr... - 0 views

    Combination immunotherapy of squamous cell carcinoma of the head and neck: a phase 2 trial.
    Barrera JL, Verastegui E, Meneses A, Zinser J, de la Garza J, Hadden JW.
    Arch Otolaryngol Head Neck Surg. 2000 Mar;126(3):345-51.
    PMID: 10722007

    The natural cytokine mixture is a collection of natural human cytokines induced from human peripheral blood mononuclear cells. It contains IL-1, IL-2, IL-6, IL-8, IL-10, IL-12, interferon gamma, tumor necrosis factor , and granulocyte-macrophage and granulocyte colony-stimulating factor in nanogram quantities. It lacks IL-3, IL-4, IL-5, and IL-7.


    This IRX-2 strategy uses perilymphatic local administration along with contrasuppression with low-dose cyclophosphamide and indomethacin and with zinc replacement therapy (as an immunorestorative). The data presented herein demonstrate that H&N SCC can respond very well to immunotherapy: there was a response rate of 100% in this series of 15 patients, with clinical reduction in tumor (1 complete response, 7 partial responses, and 7 minor responses) and histological evidence of tumor regression of 42%. Overall, the average combined estimated tumor reduction exceeded 70%. Also, patients with oral cancer noted marked analgesic and hemostatic effects from this therapy, with healing of oral lesions.


    It is important to note that adjuvant chemotherapy is not used at INCAN. Many studies23 indicate that treatment with fluorouracil and cisplatin, the combination most in use, is effective for reducing tumors in the majority of patients; however, with no meaningful impact on survival, their routine use in the United States has recently been questioned.24-25 The expense, toxic effects, and lack of effectiveness of both drugs has made their use in other less affluent countries unwarranted. The current data on the use of IRX-2 in this and other protocols8-10 hint at improved survival, and a phase 3 randomized controlled study comparing this protocol with chemotherapy arm is to be initiat
Matti Narkia

Aldehyde dehydrogenase 2 and head and neck cancer: a meta-analysis implementing a Mende... - 0 views

    Aldehyde dehydrogenase 2 and head and neck cancer: a meta-analysis implementing a Mendelian randomization approach.
    Boccia S, Hashibe M, Gallì P, De Feo E, Asakage T, Hashimoto T, Hiraki A, Katoh T, Nomura T, Yokoyama A, van Duijn CM, Ricciardi G, Boffetta P.
    Cancer Epidemiol Biomarkers Prev. 2009 Jan;18(1):248-54.
    PMID: 19124505
    doi: 10.1158/1055-9965.EPI-08-0462
Matti Narkia

Safety evaluation of topical applications of ethanol on the skin and inside the oral ca... - 0 views

    Safety evaluation of topical applications of ethanol on the skin and inside the oral cavity.
    Lachenmeier DW.
    J Occup Med Toxicol. 2008 Nov 13;3:26.
    PMID: 19014531
Matti Narkia

Erbitux Increases Overall Survival For Head And Neck Cancer Patients - 0 views

    Erbitux (Cetuximab), a new drug which is used in combination with chemotherapy, increases overall survival in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck, according to ImClone, the company which introduced the dr
1 - 16 of 16
Showing 20 items per page